(RTTNews) - Pro-Dex Inc. (PDEX), a developer and manufacturer of powered surgical instruments, on Friday announced that it executed a contract amendment on December 17, 2025, with its largest customer, extending the agreement by three years.
The agreement, which covers Pro-Dex's powered surgical instruments, was scheduled to terminate on December 31, 2025, but has now been extended through December 31, 2028. It also contains minimum purchase volumes for the 2026 and 2027 calendar years.
"This amendment will culminate in more than fifteen years of collaboration with this customer and positions us for continued revenue growth," said Richard L. Van Kirk, the company's President and CEO.
For the fiscal first quarter ended September 30, 2025, Pro-Dex generated net sales of $18.5 million, up 24% from $14.9 million in the prior-year period.
Net income rose to $4.7 million, or $1.40 per diluted share, compared to $2.5 million, or $0.75 per diluted share a year earlier. The increase was driven primarily by resumed shipments of the company's next-generation surgical handpiece to its largest customer.
Looking ahead, Pro-Dex expects the extended contract to provide stability as it continues to innovate in surgical instrumentation and expands consulting services.
PDEX has traded between $23.47 and $70.26 over the past year. The stock closed Friday's trading at $38.68, down 8.30%, and rose in after-hours trading to $41.10, up 6.26%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
